Bromocriptine and suppression of postpartum lactation
- 47 Downloads
The use of bromocriptine for the suppression of postpartum lactation drew widespread attention to a potentially increased risk for cardiovascular and cerebrovascular adverse effects. To estimate the incidence of these events a follow-up study was performed among 2,130 women of 15–44 years of age who were treated with a course of bromocriptine in 1990–1992. None of these women were admitted to the hospital for cardiovascular or cerebrovascular events. However, the incidence of pregnancy hypertension and the use of cardiovascular drugs increased considerably in the last 2 months before delivery. Therefore, cardiovascular or cerebrovascular events can probably be explained by pre-existing morbidity rather than by the use of bromocriptine. We estimated, using a ‘worst-case’ analysis, that fewer than 2 Dutch women each year would develop serious cardiovascular or cerebrovascular events.
KeywordsAdverse effects Bromocriptine Cardiovascular diseases Cerebrovascular disorders Incidence Lactation Product surveillance, postmarketing
Unable to display preview. Download preview PDF.
- 1.Postpartum hypertension, seizures, strokes reported with bromocriptine. FDA Drug Bull 1984;14(1):3–4.Google Scholar
- 8.FDA to act on Sandoz Parlodel®. Scrip 1993;1855:10.Google Scholar
- 9.Woodcock J. Bromocriptine mesylate: withdrawal of approval of the indication for the prevention of physiological lactation. Fed Reg 1995;60(19):3404–5.Google Scholar
- 10.Herings RMC. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in the Netherlands [dissertation]. Utrecht: Utrecht University, 1993.Google Scholar
- 11.Anatomical Therapeutic Chemical (ATC) classification index: Including defined daily doses (DDD) for plain substances. Oslo: World Health Organization, 1992.Google Scholar
- 12.WHO. International Classification of Diseases. 9th Clinical Modification (ICD-9-CM). Geneva: World Health Organization, 1987.Google Scholar
- 13.Vademecum of health statistics of the Netherlands 1993. ′s-Gravenhage: Netherlands Central Bureau of Statistics & Ministry of Welfare, Health and Cultural Affairs, 1993.Google Scholar
- 14.Fournié A, Graille V, Montastruc JL. Bromocriptine, lactation inhibition and pharmacovigilance. J Gynecol Obstet Biol Reprod 1994;23:129–30.Google Scholar
- 16.Vandenbroucke JP, Hofman A. Grondslagen der epidemiologie [Fundamentals of epidemiology]. Utrecht: Bunge, 1993.Google Scholar
- 17.Healey M. Suppressing lactation with oral diuretics [letter]. Lancet 1961:1353–4.Google Scholar
- 18.De Jong-van den Berg LTW. Drug utilization studies in pregnancy: what can they contribute to safety assessment? [dissertation]. Groningen: University of Groningen, 1992.Google Scholar